Back to search results

Shared Decision Making for Oral Anticoagulants

This study is testing a new tool called DDInteract to help you and your doctor make decisions about drug interactions when you are taking oral anticoagulants (blood thinners like warfarin, apixaban, edoxaban, dabigatran, or rivaroxaban). This tool is built into your electronic health record (EHR) and helps calculate your risk of bleeding, especially in the stomach or intestines, from drug interactions. It also lets you explore different treatment options with your doctor. The study aims to see if using DDInteract can reduce your risk of gastrointestinal bleeding. You may be able to join if you are at least 21 years old and take more than one oral anticoagulant. The study is currently evaluating how well this tool works in clinics at the University of Utah, University of Colorado, and University of Vanderbilt.

Study design
This study is an interventional, cluster randomized trial involving clinics at three universities, with a planned enrollment of 3691 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, differences in estimated risk of gastrointestinal bleeding, will be measured through study completion, which includes an 18-month implementation period and a 12-month baseline period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06401863

Shared Decision for Drug Interactions in Oral Anticoagulation

Active, Not Recruiting
NAAges 21+InterventionalPrevention
University of Utah
~3,691 participants
Updated 2026-06-26 on ClinicalTrials.gov
What's tested:Shared Decision Making Tool

At a glance

Recruiting sites
0 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Differences of Differences in Estimated Risk of Gastrointestinal Bleeding by DDInteract algorithm
Measured over Through study completion, an average of 18 months for the implementation period and 12 months for the baseline period clinics

Conditions

Anticoagulants
Drug Interactions

Explore related trials

Anticoagulation

Where it's being run

3 sites across 3 states
Colorado1
Tennessee1
Utah1

Study leadership

  • Daniel C Malone, PhD · PRINCIPAL_INVESTIGATOR · College of Pharmacy. University of Utah

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Be at least 21 years of age or older
Receive more than one prescription of an oral anticoagulant (i.e. warfarin, apixaban, edoxaban, dabigatran, rivaroxaban)

Exclusion

Individuals not able to speak English or Spanish

What this trial measures

  • Differences of Differences in Estimated Risk of Gastrointestinal Bleeding by DDInteract algorithmThrough study completion, an average of 18 months for the implementation period and 12 months for the baseline period clinics

    We will compare population Gastrointestinal Bleeding risk across the randomized clinics before and after implementation of DDInteract